ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 734

The Role of Micro-RNA 142-3p Expression in Lupus Nephritis in an Egyptian Cohort

Marwa Elkhalifa1, Magdy Zehairy1, Manal Tayel1, Ahmed Elkeraie2, Dalal Elkaffash3 and Nahed Baddour4, 1Internal medicine, Rheumatology, Faculty of medicine, Alexandria University, Egypt, Alexanderia, Egypt, 2Internal medicine, Nephrology, Faculty of medicine, Alexandria University, Egypt, Alexanderia, Egypt, 3Clinical and Chemical Pathology, Faculty of medicine, Alexandria University, Egypt, Alexanderia, Egypt, 4Pathology, Faculty of medicine, Alexandria University, Egypt, Alexanderia, Egypt

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: MicroRNA and lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Micro-RNAs play an important role in regulating gene expression at the posttranscriptional level. Recent data have shown that microRNAs are critical for the development and function of immune system, both innate and adaptive immunity.(1,2) MicroRNAs are differentially expressed in patients with systemic lupus erythematosus (SLE), especially in association with lupus nephritis.(3,4) The heterogeneity of patient ethnicity and variety in detection method may in part explain some of the discrepancies of positive micro-RNA list in SLE patients in different studies. Testing serum or urine microRNA expression would offer a promising tool to illustrate the pathogenesis of SLE, provide novel biomarkers and potential therapeutic soption.(5)

Methods:

Expression levels of micro-RNA-142-3p extracted from peripheral blood mono-nuclear cells determined using quantitative reverse transcription–polymerase chain reaction assay. A total of 90 plasma samples were obtained from 30 SLE patients without clinical and laboratory evidence of lupus nephritis, 30 SLE patients with lupus nephritis and 30 healthy control subjects.

Results:

The expression of micro-RNA-142-3p in SLE patients was significantly lower than the expression in normal healthy control, p<0.001.In addition the Roc curve of micro-RNA-142-3p showed that micro-RNA-142-3p expression levels can significantly discriminate between lupus patients with and without lupus nephritis at a cut off level ≤5.7×10-6 with a sensitivity of 83.33% and specificity of 90% .We also found a significant correlation between micro-RNA-142-3p expression levels and the pathological activity index of renal biopsy, while there was no significant correlation between micro-RNA-142-3p expression level and the pathological chronicity index.

Conclusion:

The expression level of micro-RNA-142-3p could be considered a diagnostic marker of SLE. Also, the expression level of micro-RNA-142-3p could be considered a potential biomarker for recognition of renal involvement in SLE patients.

References : 1. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol 2016;16:279-94.
2. Liu J, Qian C, Cao X. Post-translational modification control of innate immunity. Immunity 2016; 45:15–30.
3. Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16 :939–46.
4. Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, Kelly JA, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010;5(5): e10344.
5. Wang Z, Chang C, Peng M, Lu Q. Translating epigenetics into clinic: focus on lupus. Clin Epigenetics 2017; 9:78.


Disclosure: M. Elkhalifa, None; M. Zehairy, None; M. Tayel, None; A. Elkeraie, None; D. Elkaffash, None; N. Baddour, None.

To cite this abstract in AMA style:

Elkhalifa M, Zehairy M, Tayel M, Elkeraie A, Elkaffash D, Baddour N. The Role of Micro-RNA 142-3p Expression in Lupus Nephritis in an Egyptian Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-role-of-micro-rna-142-3p-expression-in-lupus-nephritis-in-an-egyptian-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-micro-rna-142-3p-expression-in-lupus-nephritis-in-an-egyptian-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology